| Literature DB >> 32732679 |
Abstract
Mantle cell lymphoma is a rare, aggressive, and largely incurable form of non-Hodgkin lymphoma. There are a number of well-characterized prognostic features but nothing that can help guide therapy. Treatment with chemotherapy is generally effective in the short term, but relapse is inevitable and subsequent treatment is challenging. The use of Bruton tyrosine kinase inhibitors, however, has transformed practice. These agents are highly active in relapsed disease and are very well-tolerated drugs. Chemotherapy-free combinations using Bruton tyrosine kinase inhibitors look very exciting and will likely evolve to be part of frontline care in the future.Entities:
Mesh:
Year: 2020 PMID: 32732679 DOI: 10.1097/PPO.0000000000000462
Source DB: PubMed Journal: Cancer J ISSN: 1528-9117 Impact factor: 3.360